Charity Registration No. 1134859ISC039721
Company Registration No. 07127101 IEngland and Wales)
REPORT OF THE TRu>fEES AND
AUDITED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
FOR
NATIONAL RHEUMATOID ARTHRITIS SOCIETY

NATIONAL RHEUMATOID ARTrfRIYIS SOCIETY
LEGALAND ADMINISTRATIVE INFORMATION
Trustees
Mr R Bain5
Mr R A Boucher
Mrs Collin5
Mr R Flowerdew
Mr J Jordan
Profe550r PTaylor
Mrs A Woolf
Miss C Ward
CEO
Mr5 Cjacklin
Charity number
11348591 SC039721
Company number
07127101
Reg15tered office
Sulte 3, Beechwood
Grove Busines5 Park
White Walthèm
Maldenhead
Berks
SL6 3LW
Audltors
MO0￿ Kingston Smith LLP
The Shlpping Bullding
The Old Vlnyl Factory
Blyth Road
Hayes
U83 IHA
Bankers
HSBC
35 High st￿et
Maidenhead
SL6 UQ

NATIONAL RHEUMAYOIDARTHRIT15 SOCIVY
CONTENTS
Tru5tees' report
1-13
Staternent of Trustees, resrx)nsibilities
12
Staternent asto disclosu￿ to our auditors
13
Independent audltors. report
14-17
Consolldated Ststement of finantial a£tivities
18
Company Statement of flnanclal activities
19
Consolidated and Company Balance Sheets
20
Consolldated Statement of Cash Flows
21
Note5 tothe accounts
22-36

NATIONAL RHEUMATOID ARTHRITIS SOCIE
TRUSTEES, REPORT (INCLUDING DIREcfoRS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2023
The Trustees present their report and audited consolidated account5 for the year ended 31
December 2023. The Trustees have adopted the provisions of the Statement of Recommended
Practice ISORPI "Accounting and Reporting by Charities" IFRS 102} in preparing the annual report
and finaftcial statements of the Charity.
The accounts have been prepared in accordance with the accounting policies set out in note I to the
account5 and comply with the Charity's governing document, the Charities Act 2011, the Companies
Act 2006 "A¢countin8 and Reportins by Charities.- Statement of Recommended Practice
applicable to charities preparing their accounts in accordance with the Financial Reporting Standard
applicable in the UK and Republic of Ireland IFRS 1021 (effective l January 20151."
Chairfs Report
It'5 really heartening to be able to report that 2023 was a ￿markable year in many ways for NRAS, as
we successfully broke many of our own internal records for service delivery. We helped more people
than ever before by providing information and support via our Helpline team, in addition to our
online communiries includirsg Facebook, the Health Unlocked forum and online broadcasts. We also
increased the number of publication5 distributed to health care professionals and individuals alike.
with our Benefits and Fatigue booklets beinB the most requested this year. Seeking to reach and
assist people in new ways, we continued to develop our online suite of self-management module5
(SMILE RAI and reached over 4.0(Xl registrants by the end of the year.
A5 well as breaking records for the number of people we serve. we also reported one of our strongest
set of financial results to date with record-breaking income of £1.87m. Reco8nising the very difficult
fundraising situation, at the start of the year we had budgeted to record a deficit, planning to use our
strong reserves position to enable us to continue to deliver services at existing levels despite
anticipated funding reductions. In practice, l am pleased to report that the deficit in the year was
turned around and we actually reported a net gain of over £400k, largely due to significantly higher
than expected income from legacy bequest5. In common with nearly all charities. our experience is
that fundraising across all other areas remains challenging and whilst we are always enormou51y
grateful to all those who so generously leave bequests to NRAS. broadening and diversifying our
income stream5 continues to be one of our most important objectives, both to grow funding in
ab501ute terms and to increase its Stability arsd p￿diCtabIlity.
Some key Suc￿sseS during 2023 include:
- a highly successful nationwide survey gathering data on the impact of stress on rheumatoid
rthritss symptoms. This Is now being used in the development of a new resource for patients called
'Stress Matters,
- a substantial increase in our reach during RA Awareness Week via a 'fatt or fiction, quiz
- an increase in engagement with monthly NRAS broadcasts on an array of tOPiCS With prestigious
guest speakers and panel members
- further development of resources for UK South Asians living with RA
Piloting the JIA Right stsrt programme

NATIONAL RHEUMATOID ARTHRITIS 50CIEri
TRUSTEES. REPORT (INCLUDING DIRE￿oRs, REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2023
After such a successful year on so many counts. it is therefore with sadness that I have to report that
in December our CEO. Clare Jacklin, indicated her intention to step down as Chief Executive in 2024
after 5 years at the helm and a total of 17 years with NRAS. We owe a huge debt of gratitude to Clare
who took over running the charity in summerof 2019. just ahead of the global COVID pandemic
which hit us in early 2020. Clare successfully led the charity through those turbulent pandemic years
and implemented many changes to the organi5ation to meet the evolving needs of our beneficiaries.
It is beholden upon me to say on behalf of all the Trustees, Advisors. colleagues and Members. a
massivè thank you to Clare for her dedication and inEpirinE leadership before she leaves us in July
2024. Clare will be replaced as CEO by Peter Foxton who joins us after a successful career at Phyllis
Tuckwell Hospice Care where he was Director of Income Generatlon.
Finally, it goes without saying that none of the g￿at achievements I have described above would be
Possible without the tremendous efft)rts of our colleagues and volunteers, together with the
generosity of our funders. We are fortunate indeed to be able to rely on the efforts and skills of our
committed team and I would like to tske this Opportunity to thank you all on behalf of the Board.
Simon Collins
Chair of Trustees

NATIONAL RHEUMATOID ARTHRITIS socIErY
TRUSTEES, REPORT (INCLUDING DIREcfoRS' REPORTI
FOR THE YEAR ENDED 31 DECEMBER 2023
Our purpose and activities
Guidance from the Charity Commission has been used to review and develop NRAS'5 aims and
objectives so that activities are clearly focused to derive good public benefit.
ObJettive5 and activities
The objects of the Charity Ithe "Objects") are for the public benefit to promote the relief of people
living With Rheumatoid Arthritis IRAI and Juvenile Idiopathic Arthritis IJIAI by:
Raising awareness and understanding of RA and JIA, including awareness of the severity of the
diseases and their social and economic costs-
Providing information on RA and JIA, including information on their treatments and drugs available:
Advancing all aspects of the care and treatment of RA and JIA and the management of these diseases
in their totality;
Providing education on the diseases generally and to individua15 and their families and carers in all
aspects of RA and JIA, including their treatment and management, and providing information about
available SUPFK)rt,'
Supporting individuals in relation to RA and JIA and their families and carers, including putting
people in touch with each other to encourage self-help and support where appropriate.
Workin8 alongside NHS rheumatology health professionals to provide the best care for patients a5
well as support the clinical staff in their role5.
Our vlslon and mlsslon
Our vision is life without limits for all those with RA and JIA.
Our mission is to enable the RA and JIA community to thrive by providing access to 5UPPOrt, expert
knowledge, engagement, campaigningi and research, all of which is informed by those living with
these complex, and currently incurable. auto-immune diseases.
Underpinning all of these mission goals is our commitment to-
Improving the equality and equity of access to the best care across the UK:
Providing and promotin8 the best SUPPOrted self-management resources for those Ilving with RA and
JIA-
Harne55ing digital 501utions to meet the changing requirements of the individual and the NHS,.
Analysing the impact of our services to better inform our future plans:
Ensuring the sustainability of the charity and its services by investigating opportunitles for longer
term engagement with funders and paid-for NRAS services,.
Investing in the continuous development of NRAS colleagues, Volunteers, Ambassadors and Trustees
ensuring we maintain the highest level of expertise and knowledge to support our beneficiaries and
govern the organisation.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES, REPORT {INCLUDING DIRECTORS, REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2023
Our principal activities
We are committed to providing 5UPPOrt, evidenced-based information, services, education,
campaigning and patient advocacy of the highest quality to, and on behalf of all, those affected by RA
and JIA as well as their families. We also support health professiona15 in the field of rheumatology and
primary care through provision of free health professional membership of NRAS and free patient
IEfeiidl prLTr¥f*atnme and Informatlon 50 that we can help them to help thelr patlents.
Our front-line seNices include:
A Helpline which operates 30 hour5 per week and is managed by a team of four colleagues,.
An online peersupport community;
Local and virtual groups,.
A peer-to-peer telephone support programme,.
A supported self-management modular e-learnin8 pro8ramme,'
Information booklets,.
Websites packed with information and downloadable resources,.
Patient events Iboth in person and virtually)
A membership scheme
LNing with RA and JIA is not just about having physical and medical needs. These incurable diseases
have a huge impact on emotional wellbeing and quality of life on both the individual and their familv.
We will continue to strive to help people by supporting all their needs in a holistic way whether
physical, medical, emotional, mental, social, economic and/or employment related needs as well as
those relating to acce5S to benefits.
We are at the table at a national level whenever standards and guidelines, RA/JIA pathways and
access to treatment are being discussed. We conduct our own social research and publish key
reports on a topic of importance to people with RA/JIA periodically.
Translational scientific and medical research has revolutionised the field of auto-immune conditions
such as RA and JIA in the last few decades and whilst we do not fund medical research ourselves, we
do 5UPPOrt a growing number of academic and clinical research studies throughout the UK on an
ongoing basis. We also support recruitment to clinical studies and provide expert volunteers to
advise on issues of Patient and Public Involvement. We do on occasion conduct our own funded
major social research studies often in partnership with an academic institute. In 2023. IEXAMPLEI.
In 2023, we continued the development of our suite of e-learning self-management programmes,
devised and produced by our founder and now National Patient Champion, Ailsa Bosworth MBE. We
now have a total of seven modules freely available for anyone to access on our website and work will
soon start on our largest and most complex module to date, Cardiovascular Disease Risk
Management. In 2024 we plan a strong campaign to encourage even more health professionals to
utilise the SMILE modules for patient education by signposting people living with RA to register for
the programme.
We also launched a new service in 2023 which aims to support families with a child diagnosed with
juvenile idiopathic arthritis IJIAI. This new seNice is modelled on our service for rheumatoid arthritis,
New2RA Right Start. and is called New2JlA Right Start

NATIONAL RHEUMATOID ARTHRITIS SOCIErY
TRUSTEES, REPORT (INCLUDING DIRE￿oRs, REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
Achievements, performance and flnanclal review
Net income increosedfrom £1.65m to £1.87m
HOW WE RAISED OUR MONEY
2022 w 2023
lJGI.Jk
E?10. J< k
134.7k
DONATIONS AND
GIFTS
LEGACIES
CHJIRITABLE
ACTIVITIES
OTHER TRADING
ACTIVTIES
INVE5TMFNT
INCOME
The Charity increased overall income by 13% in 2023 to £1.87m making this the Charivs most
successful income generation year on record. This performance was dominated by legacy bequests
where reported Ènr.nmp rpached £l.04m, up 35% on 2022. Legacy intome represented over 56% of
the Charity's total income in 2023 and we remain immensely grateful to our very generous
benefactors whose 8ifts enable us to continue to deliver our much-needed services and which will
also provide funds to enable us to invest in enhancement5 to those services and new innovations
especially as we enter a health environment more focu55ed on delivering Se￿iceS digitallv.
Income from donations and gifts was largely unchanged overall from 2022 delivering £561.5k of
income, a commendable achievement given the continued pressure5 on traditional fundraising
streams being felt across the sector. These figures also include funds received from pharmaceutical
companies who manufacture and market medicines for RA andlor JIA. This income amounted to
£92.4k in 202312022-. £166.3kl. As well as helpin8 to fund the core setvices that we deliver to our
beneficiaries, these relationships provide NRAS with access to important information about clinical
trial data and help to inform and educate our team members on RA and JIA. NRAS is now perceived
by most pharmaceutical companies working in the area of immunology and rheumatology as a key
expert partner in contributing to advisory boards and employee training, as well as providing 5UPPOrt
in the development of their own patient-facing support resource5.
The Charity also operates a variety of membership schemes for those living with RA or JIA, their
families and health care professiona15. These schemes provide access to a members, forum, monthly
newsletters and a bi-annual magazine full of interesting articles and information. Income from the
membership schemes totalled É85.4k in 20231£2022: £83.Ikl.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES. REPORT IINCLUDING DIRECTORS. REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2023
Support for NRA5 was also weieived through grant5 from trusts and foundations and In 2023 this
amounted to £72.6k12022'. £137.Okl. We would like to express particular thanks to the following
organi5ations who all donated £2.000 or over each.- National Communities Lottg.rip.% Fijnd, Thp
Childwick Trust, The February Foundation, The John Coates Charitable Trust, Stancourt-Dicker
Charitable Trust, Vandervell Foundation, The William and Mabel Morris Charitable Trust, The Joseph
Strong Frazer Foundation, The Charles Littlewood Hill Trust and D'oyly Carte Charitable Trust.
A growing area of income generation for the Charitv is in the field of social rèsearch where we work
with academic partners, pharmaceutical companies or other organisations to help develop and
deliver new services to best meet the needs of all those we Serve as well as campaign to effect
change with government, the NHS and those who commi55ion health and social care services. In
2023 income generated from research activities totalled £29.2k12022'. £8.3kl.
All income received through fundraising in 2023 contributed to enabling the Charity to provide a full
programme of resources, activities and support, which benefits those living with RA and JIA in the
UK, their farnilies, schools and the healthcare profe55ionals who care for them. NRAS would like to
acknowledge and thank all the individuals, companies, trusts and foundations that have supported
our work this year.
Total expendlture decreasedfrom £1.79m to £1.53m
HOW WE SPENT OUR MONEY
2022 w 2023
INFORMA TION &
SUPPORT
RA5SING
AWARENESS
COMMUNITY
SUPPORT
SUPPORTINS
YOUNGER PEOPLE
INNOVATIONS
Overall expenditure reduced by 14.7% cotnpared with the prlor year, thanks partly to the successful
office relocation undertaken in late 2022 as a result of which annualised office-related costs reduced
by nearly 40%.
Employee numbers remalned largely unchanged with the full time equivalent team numbers down
from 27 in 2022 to 26 in 2023. Thi5 helped keep overall employment Costs growth down to just 1.4%
in 2023.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES, REPORT (INCLUDING DIRECTORS. REPORTI
FOR THE YEAR ENDED 31 DECEMBER 2023
The Charity reported a 8ain on its investment portfolio of over 7%, equivalent to £65.8k.
The Charity reported a consolidated net surplus of £403.9k in 2023, compared with a net deficit of
£288.6k in 2022.
The Charity's wholly owned trading 5ub5idiary, NRAS Community Services Limited, was largelv
dormant in 2023. The company delivered a small10ss of £O.Ik on its activitie5.
Balance sheetshow5 net assets of £2.Om
Net assets in the year increased by £403.9k reflecting-
Gains on revaluation of investments of £65.8k
An increase of £358.5k on cash at bank
A Small decrease of £20.4k on fixed assets and other current assets.
ReseTh￿s policy
Unrestricted reserves totalled É1,997.4k ot the end olthe yet7r.
The Charity continues to set aside designated reserves to support the continued delivery of its core
services for the upcoming twelve months and a150 to cover potential inve5tment105ses. These
designated funds in aggregate amounted to £600k as at 31 December 2023. The Charity also
continues to hold a minimum of six months, operating costs in cash and investments. Investments
and cash balances as at 31 Dg.rpmbp.r 2024 wp.rp. valtjpd in aggrpgxtp at £1,676k eivinB rise to an
operatin8 Cost coverage of 13.15.
Free re5erve5 85 dl 31 D¥Leriiber 2023 w¥re E624.7k12022- £473.4kl. Free reserves are defined a5
unrestricted funds which have not been earmarked and may be used generally to further the
charity's objectives.
HOW OUR UNRESTRICTED RESERVES ARE ALLOCATED
2,500,000
2,000,000
632,471
1.500.000
473,360
t£ 1,000,000
764,879
895,727
500,000
2022
2023
De5igiidted fund5
6 month5 operating co515
Sui-plus free reserves

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORTI
FOR THE YEAR ENDED 31 DECEMBER 2023
We will work hard to ensure that our fund5 are used judiciously so that we return the biggest benefit
to our beneficiaries for each pound invested. We will continue the expansion of our supported self-
management suite of modules and broaden our digital offerings as well invest in campaigns to raise
awareness of RA and JIA.
Going concern
The churity contlntse5 to preporefinoncialstatements on the basis thot ITt is a going concern.
Our healthy cash balance and investment portfolio means that we have sufficient liquidity to ensure
that we can meet our future obligation5 as they become due for the foreseeable future.
Fundraising prattices
The charity complies with the regulatory standards for fundraising. We are registered with the
Fundraising Regulator and are committed to the Fundraising Promise and adherence to the Code of
Fundraising Practice. This report covers the requirements charities must follow as set out in the
Charitie5 Act 2011 and the Charities Social and Protection Act 2016.
Our fundraising effort involves encouraging donations through a variety of events. applying for funds
from grant-making bodies and operating a weekly lottery. Our fundraising team comprises paid
employees only and we do not use the services of any professional fundraisers. All direct marketin8
is undertaken by the fundraising department to ensure that it is not unreasonably intrusive nor
persistent. All markctins material contains clear in5truction5 011 Iluw la person can be removed from
mailing lists.
We operate our lottery compliantly under licence from our local authority and all administration is
handled by a certified External Lottery Manager with the Gambling Commission.
Our website outlines our complaints policy for the public and clearly explains how an individual can
complain. We received no complaints this year in relation to fundraising artivities.
We have published our vulnerable persons policy on our website. In addition to our policy we have
an agreed operating procedure to protect vulnerable people. Our fundraisers, who are all paid
employees, are familiarised with the code of conduct to ensure that it is applied properlv.
Investment Policy and Objectives
Longer-tem a55ets are invested with the aim of at least maintaining the real value of capital li.e.
against inflation) within an appropriate risk profile. The ChariVs investment objertives are to invest
for the long-term (five years plusl in a diversified portfolio ensuring that there is sufficient liquidity
available to fund any shortfalls or unfunded commitments.
Investments are managed by external professional fund managers as permitted by the relevant acts
and the charity commission guidelines. The Charity aims to be a responsible investor and its
professional fund manager5 are expected to take account of Environmental, Social and Governan
IESGI issuetr in their investment analysis and deci5ion-Inakiii8 PIULES) 6nd to engage wlth Irusiee5
when appropriate, including the provision of periodic reports covering ESG issues.
Investment performance reports are received quarterly from the fund managers and the Trustee5
review performance annually with the fund manager5.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES. REPORT {INCLUDING DIREcfoRS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2023
Future plans
The Trustees approve and adopt Strategic plans for the Charity every three years and detailed
budgets are prepared annually to support these initiatives and demonstrate how the objectives will
be delivered within the constraints of predicted funding available. The budget is reviewed on a
quarterly basis arid appropriate management decisions are taken in light of any material forecast
variances.
The Cliarlty Ts wiuw in the ftnal year of Its current srrategic plan which set out how the Charity would
continue to support and stand shoulder-to-shoulder with the entire rheumatology community
working towards our vision of life without limits for all living with RA and JIA. Work is already
underway to construct an ambitious plan to take the Charity forward over the next three year5 and
to identify how best we can serve our communitie5 in ever more challenging times for the health
sector as a whole.
We expect to continue to work collaborattvely to remove barriers to being able to access the right
treatment, at the right time in the right place, provided by the right professional. We will continue to
work to reduce discrimination within the workplace and the wider society towards people with
inflammatory arthritis. We will also champion the best evidence-based healthcare provision no
matter where in the UK someone lives and we will support all those who work within the health
service to provide the best holistic care without being hampered by a system with prevents them
from achieving this.
Strurtur•.. gov•rnance and mana8•m•nt
Governing docurnent
The Charity is controlled by its governing documents. the memorandum and articles, and constitutes
a limited by guarantee company as defined by the Companies Art 2006.
The Charity is a company limited by guarantee and does not have any share capital.
None of the Trustees has any beneficial interest in the company. All of the Trustees are members of
the company and guarantee to contribute £1 each in the event of a winding up.
Trustees
The Trustees, who are also the director5 for the purpose of company law, and who served during the
year and to the date of approval of these accounts were..
Mr R Bains (appointed 22 September 20231
Mr RA Boucher
Mr S Collins Ichairl
Ms L Cook (resigned 13 June 20231
Mr R Flowerdew
Mr D Holloway (appointed 22 September 2023 and resigned 4 January 20241
Mr J D Jordan ITreasurerl
Ms E Potter (resigned 5 December 20231
Professor P Taylor
Miss C Ward lappointed 23 June 20231
Ms S Webb Iresigned 5 December 20231
Mrs A Woolf

NATIONAL RHEUMATOID ARTHRIT15 SOCIETY
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORTI
FOR THE YEAR ENDED 31 DECEMBER 2023
As set out in the articles las amended in June 20191, Trustees are required to retire after three years
in office. A retiring trustee shall be eligible for re-election. Mr J D Jordan will therefore retire from
office at the AGM on 18, June 2024 and will seek re-election.
Trustee inductlon and training
New Trustees are briefed on their legal obligations under Charity law, the content of the constitution
and decision-making prnrgE%, the hiJsing<% plan and recent financial performance of the Charity. As
part of the proce55 they meet key employees and other Trustees and may attend additional. relevant
external training as required.
Organisation
The body of Trustees consists of not fewer than four and no more than twenty trustees and
administers the Charity through the Senior Executives.
Related parties and co-operation with other organisations
None of our trustees receives remuneration or other benefit from their work with the charity. Any
connection between a trustee or senior manager of the charity with a supplier or other party with
which the Charity transact5 must be disclosed to the full board of trustees. In the current year no
such related party transactions were reported.
Pay policy for senior staff
Remuneration for key management personnel is benchmarked against the voluntary sector and is set
by the Trustees. The pay of senior staff is reviewed annually and normalty increased in accordance
with average earnings.
10

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORTI
FOR THE YEAR ENDED 31 DECEMBER 2023
Rlsk management
The trustees have a risk managementstrategy Intludffng qf0rn7al risk evaluation whffch is carried
out each yeor.
Risk Category
Financial performance and resilience
Significant reduction in income streams and
cashflow due to economic climate could affect
the future viability of the Charity
Mitigation and Actlons
Fundraising strategy focusing on provision
of regular, predictable, unrestricted income
streams
Annual budget setting proce55 and
quarterly reviews with focus on cash flows
and financing of operational plans
Monthly management account5 detailing
key performance indicators and reserves
coverage
Protecting the Charity's assets
Market fluctuations caused by economic
instability could negatively impact our
investment portfolio and reduce the financlal
assets available to the Charity.
Investment policy is set so as to maintain
an appropriate and prudent risk strategy
Investment5 are managed by qualified
external advisers
Maintaining a stable team
Competitive recruitment markets resulting in
high levels of vacancies could impact our ability
to deliver our full range of core services and
lead to over-reliance on key members of the
team
Regular benchmarking of remuneration
packages to ensure competitive within the
charity sector
Continue to prioritise stsff wellbeing to
maximise retention
Work continues on succession planning
IT Security
Failure to ensure Integrity and security of data
ould lead to data loss or theft, potentially
resulting in fines, reputational damage and
impact delivery of our core services
Data integrity and governance including GDPR
Failure to meet our regulatory obligations could
lead to fines, reputational damage and impact
delivery of our core services
Attractlng and retaining Trustees
Failure to attract trustees with a range of skills
could affect the future viability of the Charity
Engagement of third party IT consultants to
manage our IT system5 and controls
Appointment of third party data protection
specialists to identify and monitor risks and
ensure compliance with regulations
Continue to work with our network of
partners and colleagues to identify suitable
candidates

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES, REPORT (INCLUDING DIREcfoRS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2023
Auditors
In accordance with the company's articles. a resolution proposing that Moore Kingston Smith LLP be
re-appointed as auditor of the company will be put at a General Meeting.
Tru5tees' responsibilities In relatlon to the financial statements
The Trustees, who are also the directors of National Rheumatoid Arthritis Society for the purpose of
company law, are responsible for preparing the Trustees, Report and the account5 in accordance
with applicable law and United Kingdom Accounting Standards Iunited Kingdom Generally Accepted
Accounting Practicel.
Company law requires the Trustee5 to prepare accounts for each financial year whieh give a true and
fair view of the state of affairs of the charity and of the incoming resources and application of
resources, includin8 the income and expenditure of the charitable company for that year.
In preparing these accounts the Trustees are required to..
Select suitable accounting policies and then apply them consi5tently,'
Observe the methods and principles in the Charities SORP IFRS 1021-
Make judgments and estimates that are reasonable and prudent:
State whether applicable UK Accounting Standards have been followed, subjett to any
material departures disclosed and explained in the financial statements- and
Prepare the account5 on the going concern basi5 unless it is inappropriate to presume that
the charity will continue in operation.
The trustees are responsible for keeping adequate accounting records that disclose with reasonable
accuracy at any time the financial position of the charity and enable them to ensure that the
accounts comply with the Companies Act 2006. the Charities and Trustee Investment (Scotlandl Act
2005 and the Charities Accounts Iscotlandl Regulations 2(X)6. They are also responsible for
safeguarding the assets of the charity and hence for taking reasonable step5 for the prevention and
detection of fraud and other irregularities.
The trustees are responsible for the maintenance and integrity of the corporate and financial
information included on the charitable company's website. Legislation in the United Kingdom
governing the preparation and dissemination of financial statements may differ from legislation in
other jurisdictions.
l2

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES, REPORT (INCLUDING DIREcfoRS' REPORTI
FOR THE YEAR ENDED 31 DECEMBER 2023
Statement as to disclosure to our auditors
In so far as the trustees are aware at the time of approving our Trustee5' annual report:
There is no relevant information, being information needed by the auditor in connection
with preparing their report, of which the group's auditor is unaware, and
The trustees, having made enquiries of fellow trustees and the group's auditor that they
ought to have individually taken, have each taken all steps that he/ she is obliged to take as
trustee, in order to make themselves aware of any relevant audit inforniation and to
establish that the auditor is aware of that information.
The trustees are responsible for the maintenance and integrity of the corporate and financlal
information included on the tharitable company's website. Legislation in the United Kingdom
governing the preparation and dissemination of financial statements may differ from legislation in
other jurisdictions.
S Collins
Chalr of Trustees
J Jordan
Treasurer/ Trustee
18 June 2024

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY** 

## **INDEPENDENT AUDITORS’ REPORT TO THE MEMBERS OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY FOR THE YEAR ENDED 31 DECEMBER 2023** 

## **Opinion** 

We have audited the financial statements of National Rheumatoid Arthritis Society (the ‘parent charitable company’) and its subsidiary (the ‘group’) for the year ended 31 December 2023 which comprise the Consolidated Statement of Financial Activities, (including the Consolidated Summary Income and Expenditure Account), the Group and Parent Charitable Company Balance Sheets, the Consolidated Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). 

In our opinion the financial statements: 

- give a true and fair view of the state of the group’s and the parent charitable company’s affairs as at 31 December 2023 and of the group’s incoming resources and application of resources, including its income and expenditure, for the year then ended; 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

- have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011. 

## **Basis for opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## **Conclusions relating to going concern** 

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group’s and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. 

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. 

## **Other information** 

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained in the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. 

14 



**NATIONAL RHEUMATOID ARTHRITIS SOCIETY** 

## **INDEPENDENT AUDITORS’ REPORT TO THE MEMBERS OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY FOR THE YEAR ENDED 31 DECEMBER 2023** 

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

We have nothing to report in this regard. 

## **Opinions on other matters prescribed by the Companies Act 2006** 

In our opinion, based on the work undertaken in the course of the audit: 

- the information given in the trustees’ annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and 

- the trustees’ annual report has been prepared in accordance with applicable legal requirements. 

## **Matters on which we are required to report by exception** 

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report. 

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion: 

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or 

- the parent charitable company’s financial statements are not in agreement with the accounting records and returns; or 

- certain disclosures of trustees’ remuneration specified by law are not made; or 

- we have not received all the information and explanations we require for our audit; or 

- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the trustees’ annual report and from preparing a strategic report. 

## **Responsibilities of trustees** 

As explained more fully in the trustees’ responsibilities statement set out on page 12, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so. 

## **Auditor’s Responsibilities for the audit of the financial statements** 

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts. 

15 



**NATIONAL RHEUMATOID ARTHRITIS SOCIETY** 

## **INDEPENDENT AUDITORS’ REPORT TO THE MEMBERS OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY FOR THE YEAR ENDED 31 DECEMBER 2023** 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also: 

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. 

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company’s internal control. 

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees. 

- Conclude on the appropriateness of the trustees’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern. 

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation. 

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report. 

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. 

## **Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud** 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. 

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence 

16 



## **NATIONAL RHEUMATOID ARTHRITIS SOCIETY INDEPENDENT AUDITORS’ REPORT TO THE MEMBERS OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY FOR THE YEAR ENDED 31 DECEMBER 2023** 

regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company. 

Our approach was as follows: 

- We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council. 

- We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance. 

- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance. 

- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations. 

- Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required. 

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. 

## **Use of our report** 

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity’s trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company’s members and trustees those matters which we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company’s members, as a body, and the charity’s trustees, as a body for our audit work, for this report, or for the opinion we have formed. 


Luke Holt (Senior Statutory Auditor) 

Date: 26 June 2024 

for and on behalf of Moore Kingston Smith LLP, Statutory Auditor 

The Shipping Building The Old Vinyl Factory Blyth Road Hayes, London UB3 1HA 

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006. 

17 



NATIONAL RHEUMATOIDARfHRIT1550CIETY
CONSOLIDATED STATEMENT OF FINANCIAL AcnviriES Ilnclurfing Income and Expenditure Accountl
FOR THE YEAR ENDED 31 DECEMBER 2023
Unrestrfued
Restritted
Total
U#restrfrted
Restrirted
Tot31
fund5
2023
lun
2023
lunds
2023
nds
2022
funds
2022
funds
2022
Notes
£'Of•J
£'LY)O
Donations and legacies
Charltable actSvltles
Other tradTng attDiities
Investment income
1,601.9
162.2
20.5
1,601.9
210.9
20.5
34.7
1.334.4
202.9
25.7
28.6
1,334.4
258.4
25.7
28.6
48.7
55.5
Total inrnrne
1,819.3
1,86&0
I￿91.6
55.5
1,647.1
endlture on..
Raisin8 funds
348.0
348.0
382.0
382.0
Charftèble a￿￿t￿e$
1.132.3
49.6
1,181.9
1,303.5
108.6
1.412.1
Total resourtes expended
1.480.3
49.6
1,529.9
1,685.5
108.6
1.794.1
Net incomellexpenditurel before investments
339.0
10.91
338.1
193.91
153.11
1147.01
Net 8ainsllk)55esl on Investments
12
65.8
1141.61
1141.61
Gr055 transfers between lunds
Net movement in lunds
10.91
401.9
1235.51
153.11
1288.61
Fund balances at l January 2023
Transfer between funds
l594.1
19.4
1.613.5
L871.2
141.61
30.9
41.6
1,902.1
Fund balances at31 December2023
L997.4
20.0
2A117A
L594.1
19.4
1,613
The ststement offinancial actlvltSes Includes all galns and losses recogn15ed In the year.
All Income and expendlture derlve from contlnuing attivitles.
The ststementof financial activities also complles wlth the requirements for an income and
expenditure account underthe Companies Act 2QO6.
The notes at Pa8es 22 to 36 form part olthese accounts.
18

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
COMPANY STATEMENT OF FINANCIAL ACTIVTrIES Ilncludln6 Income and EKpendlture Account)
FOR THE YEAR ENDED 31 DECEMBER 2023
Unrestrlcted
Restrirted
Totsl
Unrestricted
Restrfrted
Totsi
fund5
2023
funds
lunds
IOl3
funds
20Z2
funds
2021
funds
102Z
Flotes
£y>oo
£'LxJo
£'ooo
Income from..
Donations and le￿cleS
hartsble activities
Other trodin6 ry¢livitie3
Irwestment income
L￿1.9
162.2
1,601.9
210.9
1,339.2
202.9
L339.2
258.4
48.7
55.5
34.7
34.7
28.6
28.6
Totsl Income
1,819.3
48.7
1.868.0
1.596.4
55.5
1,651.9
enditure or+..
Raisin8fvnds
348.0
348.0
38Z.O
382.0
Charitable artimtles
1,131.2
49.6
1,181.8
1.3Tr).9
108.6
L409.5
Total resourtes expended
1.480.2
49.6
1.529
1.682.9
108.6
1,791.5
Net incorne/lexpenditurel before Snvestments
339.1
10.91
338.2
186.51
1139.61
Net galns/l1055esl on In￿stMentS
1141.61
oo
1141.61
Gross tran5fer5 between fund5
0.0
0.0
0.0
NRt movefflentln funds
404.9
0.91
404.0
1228.11
151.11
1281.21
Fund balances at l January
Transfer between funds
1.596.7
19.4
1,616.1
1,866.4
141.61
30.9
41.6
1.897.3
Fund balance5 at 31 December
10.0
2,020.1
1,596.7
19.4
1,616.1
The statement of flnanclal attivities in£lude5 all 8ain5 and Ios5e5 recogn15ed In the year.
All incon* and expendfture derfve from continuin8 activities.
The statement of financial atti¥Trlles also cofflplies with the requirements foran income and
expenditure aCCOurt under the Companies Ad 2006.
The note5 at Pa8È$ 22 to 36 form part of theseaccounts.
19

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
CONSOLIDATED AND CHARITY BALANCE SHEETS
FOR THE YEAR ENDED 31 DECEMBER 2023
Group
Charlty
2023
£'ooo
2OZ2
£'th)o
2023
E'ooo
20ZZ
£'ooo
Note5
Fixed a55ets
Intangible assets
Tangible assets
Investment5
13
13
14
26.0
36.9
1,008.5
59.6
51.0
912.5
26.0
36.9
1,008.5
59.6
51.0
912.5
1,071A
1.023.1
1,071A
1,023.1
Cvrrent assets
Debtors
Cash at bank and in hand
16
403.8
667.4
397.7
308.9
409.0
402.9
304.3
1.071.2
706.6
1.073.4
707.2
Creditors= amounts falllng due wlthin one year
17
1125.21
1116.21
1124.71
1114.21
Ntt ¢urrent assets
946.0
590.4
948.7
593.0
Totsl asset5 les5 current Ilabillties
2.017.4
1,613.5
2,020.1
1,616.1
Incomefunds
Unrestricted funds
Restritted funds
19
19
1.997.4
20.0
1,594.1
19.4
2,000.1
20.0
1,596.7
19.4
2.017.4
1,613.5
2,020.1
1,616.1
The Tru5tee5 have prepared group accounts in accordance wi(h sertion 398 of the Companles Act 2006 and sectlon
138 of the Charities Act 2011 and constltute the annual accounts requlred by the Companles Art 2006 and are forclrculatlon to
trustee5 of the companv.
These accounts are p￿pared in accordan￿ with the special provi5ion5 of Part 15 of the CompaniesAct 2006 and are for
circulation to the members of the cornpanv.
The notes at pages 22 to 36 fom part ofthese accounts.
The accounts were approved bythe Board ofTrustees on 18 June 2024
J Jordan
Irea5urtrlirustee
20

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
CONSOLIDATED STATEMENTOF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2023
Group
Charlty
2023
£'ooo
2022
2023
£'ooo
2022
Notès
Cash flows from operating actlvlties
Cash used in operations
25
358.0
178.51
359.6
173.91
Investlng artivltles
Purchase of intangible fixed assets
Purchase of tan8ible fixed assets
Purchase of investments
Interest Teceived
Gift aid donation from subsidlary
14.01
130.21
34.7
142.21
128.51
28.6
14.01
130.21
142.21
128.51
28.6
Net cash used in investln8 actlvitie5
142.11
137.31
Net dècrèase In Cash and cash equivalents
358.5
1120.61
360.1
1111.21
Cash and cash equivalents at beginning of year
308.9
429.5
415.5
Cash and cash equlvalents ai vf year
007.4
308.9
304.3
21

NATIONAL RHEUMATOID ARTHRITIS SOCIErY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DE¢EMBER 2023
1 A¢¢ounling policies
Charity infomiatitsn
National Rheumatoid Arthritis So¢￿ty i8 a prniale company limited by guarantee incorporated in England and Wales and
Scoland. Th8 registered office 1$ Suite 3, Beechwood, Grove Busirtss5 Palk. White WaNham, Bothshire. SL6 3LW
1.1 A¢countlng convention
Th•s• #ettwnts hav• pr•p*r•d ID ¥¢¢ordanto th# gO￿rnIng doeumoril. thu Compani99 Act ?.onR th
Charities and Trustee Investment Iscotlandl Act 2005, the Charities Accounts Iscollandl Regulations 2006 las 8mendedl and
'Accounting and R8POrting by Charities.. Statement of Recommended Practice applicable to charities preparing Iheir accounts in
accordance with the Finan￿al Reporting Standard applicable in the UK and Republi¢ of Ireland IFRS 1021" The charity ks a
Publi¢ Benefit Enlily as defined by FRS 102.
The accounts are Prepa￿ in sterling, which is the funcbonal currency of tha Charity. Mon•tary amounts in these financkql
ststernen15 are rounded to the nearest £'OOO.
The acLy)unts have been p￿pared undèr the historical cnst convention, modrfied lo include the rgvalu8tyon of freehakl
propEities and to indude listed inveslrnen15 and certain finanaal instruments al fair value. The prinripal accounting policies
adopted a￿ set out b910w.
Pr•paraUon of ¢on$olidai•d finan¢lal $latements
These consolidated financk81 slaternenls incorporate the finan￿al state￿ents of the Charity and its subshykqry und8rtaking,
NPAS Community Service5 Limited, made up to 31 oe￿mber 2023 Intercompany Iransaclions, balances and unrealised gains
on transactrons between the Chanty and its Subsidiary a￿ eliminated. A¢¢ounting poliaes of subsidiary undertakings have been
Changed where necessary to ensur& Consistency with the policies adopted by the Group. The income of the tiading Subsidiary is
iiitslud¥d 41 ili¥ CuiiiulKltiL¥d Sidi¥iii¥iil vf FiTI(Ili￿￿l Athwi￿¥0 wiiliiii vUi¥i I1**￿illY ¥¥bvi1￿. EApeiidiiuie i& illGludEd in sUPPOrt
costs.
1.2 Going concern
At the lirne of approving the account5, the TN5tee5 have a reasonable expe¢tatr"on that Ihe charity has adequate resources to
continue in operational existence for the foreseeable future and at least for12 months frem approval of the58 accoun15. This
expe¢latK)n is based on the strong Investments and ¢8sh position, r8fl8cting a signifi'cant arnounl of unrestricted funds and the
financi21 perfomance of the Charty. Thus the Trustees continue lo adopt the going con￿r￿ basi5 01 accounting in p￿parIng
the acwunts.
1.3 Charitable funds
Unrestricted funds are available for use at Ihe disciebon of the Trustee5 in furtherance of theTr charitable obtse¢llves.
R¢str￿led fund5 are funds which are to b8 U58d in aeccrdance spècific rostrkllons imposed by donors orwhich have been
raised by the charity for particular pu￿ose5. The cost ol raising and admini8tering such funds are charged against the spec￿1¢
fund. The aim and use ol each ￿$trICted fund is set out in the notes to the financial stat8m8nl5.
1.4 Incoming resources
Incorne 15 recognised when the charty is entiued to il after any perf0mlan￿ condib'ens have been meL the amounts can
be tneasured ￿lIablY. and rt LS probable that income will be received.
Cash donations a￿ recognised on ￿CeIpt Other donation5 are recognised cnce the charity has been notif￿￿ of Ihe donatr￿,
unless performance condit￿n8 require deferral of the arncunt. Income tsx recoverable in ￿lation lo dona*'ans re￿ived under
GIftA￿ or deeds of covenant is recognised at the time of the donation.
22

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 310ECEM8ER 2023
l Aecountlng ptslicies
Icontlnuedl
Legacrea are recognised on re￿ipt or otherwise rf the charity has been notified of an impending distribution, the amount 15
known, and receipt is probab￿. If tho amount is not known, the kgacy is treated a5 a contingent asset.
charity re￿iVeS grants in respect of charilabfe actniibes wn by the charity. Income from grants are r6cogni5ed al fair valu8
when the ¢harity has 8nlitlemenl after any perfornian￿ ¢wditr'ons have been met. It ks probable that the income wll be received
and the amount can be measured relKgbly.
Income tram trading acbvi118s Includes income eamed Irom fundraising events and trading activilies to rai8e funds for the
tharity. In¢orne is received in exchange for supplying goods and services in order lo raise funds and is recegnis8d when
8nlillement has oc¢urred.
Subscription incorne is recognised on a rolkng basis frorn Ihe date of mernbership.
Income is measured at the fair value of the consideration received or receivable and represents amounts ￿￿Nable for
se￿l¢e$ provKled in the normal course ol business. n8t of discounts, VAT and olher sales related taxe8.
1.6 R•source$ gxpended
All ex￿nditure is ac¢ountsd for on an accwals basis and has been classffied under hèadiNJs th8t 8ggreg8tè all eosts ralat8d to
the Gategory. Expenditure is recogni$ed where there is a legal or con$tructs"ve obligath.on to make payrnenls to third partie5. 1115
probable that the 58t118m8nlwll be wuired and th8 amount of the obligation can be measured reliabty. It is calegoriqeé under
the folbwing headSngs'.
Costs of raisin9 funds indude5 cos15 related to fundraising events, rnerchandisin9 and ￿VertiSIng.,
Expenditura on charitsble a¢tNitses indwles staff ¢o$ts and support costs relalng to different projects coThJu¢ted during th•
year (see note 8}.
Irrecoverable VAT i% char9ed as an expense against the a¢bvityforNvhich eXpenrfrtu￿ arose.
Support ¢o$ts allocation
Support C051s include both direct expenditu￿ incurred on charitable aclivittes and those costs which a5S15t the work of th8
charity indud1￿ office and admini81ratwe costs. They are all incurred t11￿¢11Y in the furthering of the charity's aims and
purposes. Dstinction ha5 been made for those costs relating to the raising of funds and to governance. these costs have been
analysed separatety.
Fundraising Costs are those incurred in seeking voluntary contributiens and do not indude the costs of disseminatirq
1nf0rrnat￿n in support of the tharitab￿ actNItw.
The bases on which support Costs have been allocated are set out in Note 9.
Fundraising costs are specffied in Note 7.
Govemance costs are specified in Nots 9.
Expenditure is accounted for on an accruak basis and has been ClasS￿￿d under headings that agg￿gate all costs rèLqtsd to
that category. Where costs cannot be directly attributed lo particular headings they have been allocated to activities cn a tsasis
consistent wrth the use of resourc8S.
23

NAMONAL RHELIMATOID ARTHRIT15 SOCIErY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2023
1 Accounting poli¢ieg
(Continued)
1.6 Intsnglble and tangible fixed assets and depreciation
Intangible and tangible fixed assets are initially measured at (ost and subsequentty measured at wst orvalualion, net of
depreaation and any impaimient bsses.
Depreciation is recognised so as to write off the cost or valuatson of assets ths their ￿sIdual vatues over their useful lives on
the following bases..
Improvement5 to proper
Website development
Fixtures, fittings & equipment
20% straight line or kase period rfshorter
25% straight line
25% straight line
The gain or loss arising on the d15PDsal ol an asset is determined as the difference bpiween the sale prt)ceeds and the carrying
value of the asset. and is ￿¢99n1$ed in net Inc￿e/leX￿ndit￿re} for the year.
1.7 Impaimignt of flxed assets
At each réporting date, the ¢harity rev￿5 the carrying amounts of its tangible assets to determine wh8th8r Ihèr8 is any
i￿1¢a￿"0n that those as5els have suffered an impairnent105s. If any such indicat*Jn 8￿Sts, the recoverab￿ arnount of the asset
is estimated in order lo dete￿ine the extent of the irnpainnent loss Irf any).
1,8 Cash and ¢a$h equovalents
Cash and ¢8sh eqU￿a￿￿ts include cash in hand, depDSrts held at call wlh banks. other short-terrn IiquKI investrnents with
or￿inal malurilies of th￿e monlhs or less. and bank overdrafts Bank overdrafts are shown ￿1h1n borrowing$ ￿ ojrrent
1.9 Flnancial rn8trumonts
Tha charity has 81ected to apply the provisions of Section 11 'Ba8ic Financial Inslrurnents. and Section 12'0th8r Finano81
In5ttuments Issue5. of FRS 102 to all of its financial in51rurnenl5.
Financi81 instruments are recognised in the tharitys balance Sheet when the tharity be¢ome$ party to the contractual
provisions of the instrument.
Finanaal asset5 and liabilit￿S are oftset, with the nel amounts presented in the fin8na81 statements, when there is a legally
enIor￿able tight to set off the recogni¥ed amounts and there 15 an intsntion to Sett￿ on a r￿1 basis orto ra8lis• Ihè assat and
setue the liability simullaneou51y.
Baslc finaneial assets
Basic finanGial assets, which include debtor5 and cash and banh balances. a￿ initially rnea5ured at transaction pri￿ induding
transaction CDsl$ and ar8 subsequently carried at amortised cost using th¢ effective interest method unless the arrangement
consb'tute$ a financing transactK)n. %there the transaction is measu￿￿ al the present value of the future ￿￿Ipts discountsd at
market rate of inlere$t Financial a$$ets classified as receivable wthin ane year are not amortised.
24

NATIONAL RHELJMATOID ARTHRfYis SOClErY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2023
1 ACCOUn￿n9 poll¢l•s
(Continuedl
Baslc flnanclal Ilablllfles
BasTC financial liab'lrties. including creditors and bank loans are initially ￿¢¢gnised al tran5actKn price unless the awangemenl
¢onslilule5 a financing Iransa¢tK)n. Whe￿ the debt instrument is measured at the present value of the futu￿ discountsd
at a market rate of inleresL Finantjal liabilities cksslf￿d as payable wlhin one year a￿ not amortised.
Debt instruments are subsequently Carried at amortised cost, using the effective interest rate method.
Trade creditors are obligats.ons lo pay for good5 cr serv￿e5 that have been acqui￿￿ in the ordinary course of operation5 from
suppliers. Arnounls payable are classified as current1Sabililie5 if payment is due within one year or kss. If not. they a
presented as non-currenl liabilibes Trade creditors a￿ re¢ogni5ed initially at transathon pri￿ and subsequently measurEd at
amortBed ￿$t U5in9 the effective interest methcd.
Derecognltlon of Ilnanclal Ilabllllles
Financkql liabilitie5 are d8recogni5ed when the Charity's Mntractual obltq8t¥Jns 8wr8 or are distharged or Can￿lled.
1.10 Fixed as6et investm8nts
Fixed asset inve5knents are initi81ty measured at transaction Pri￿ excluding transaclion costs. and are subsequpnlly measuted
al fair value at each reporbng dale. Change5 in fair Value are ￿¢¢gniSed in nel incomell8xpendilurel for the year. Transaction
eosts are 8xpeTrsed as incurred.
1.11 Employee bpnofits
The ￿5t of any unused hollday •ntitkment ks recognisad in the period in which the employee's servi￿5 are rèctwed.
Temiination ben&fits ar8 recognised immediately as an expense when the charity ￿ derncnstrably committed lo termllia¢e the
•mpIo￿l•￿tr of an èmployèo or to provN40 t9rn7lnst￿n bonofits.
1.12 Leases
Rentals payab￿ underoperating1885e5, including any ￿aSe incenlNes received. are charged to incorne on a strabaht line basi8
Over the terrn of Ihe ￿￿vant lease.
2 Cr6tical a¢¢ounting estimatss and judgements
In Ihe application of the charity's accounting policie5, Ihe Trustee5 are required to ma(e I￿geMents. estrmates and
assumptions about the carrying amount cf assets and liabilibes that are not readity apparent from other sources. The estimates
and asso¢ialed assumptions a￿ based on historKal expErEnce and other faclers that are con8klered to be ielevant. A¢lual
results may differ from these estimates.
The estimate5 and undedyiry assumptions a￿ ￿vieWed on an ongoing basis Revisions to accoun￿n9 estirnates ara
cognised in the period in whith the estimate is re￿￿ed where the reViS￿n affects only Ihat perirAI. or in the per￿(5 of the
revision and future perK>d5 where th8 revision affects both current an¢J future ￿riOdS.
25

NATIONAL RHEUMATOIDARTHRlnS SOCIErY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENOED 31 DECEMBER2023
3 Donatlons and legades
Group
2023
Charity
1022
2023
Z02Z
£'Th]o
£'o
£'ooo
£'ooo
Donations and Eifts
Legacle5 rerelvoble
561.5
I,U40.4
561.4
iiJ.u
561.5
566.2
I,V4V.4
1,601.9
1,334A
1,601.9
1,339.2
An01y￿S )yfvnd
Re5tiicted funds
Unrestrftted fund5
1.601.9
1,601.9
1,334.4
1,334.4
1,601.9
1.601.9
1,339.2
1,339.2
4 Inome frvrn rharitable aCti￿tIeS
Group and charity
2023
2022
£'oco
£,(￿0
Subscriptions
Lottery income
Research studies
Gron15
85.4
23.7
29.2
72.6
83.1
30.0
137.0
210.9
258.4
An¢rty515 byfvnd
Restricted fund5
Unrestrirted fund5
48.7
162.2
ZIO.9
55.5
202.9
258.4
5 oiher tradSngartiwtie5
Group and charity
2023
2022
£'ooo
Merchandislngand other tradlng Income
20.5
20.5
25.7
25.7
6 Investm¢nt$
Group and ¢harity
2021
2022
£'oc
Incomefrom listed Investments
28.6
28.6
34.7
26

NATiof4ALRHELIM4TOIDARTHRITISSOCIETY
NOTESTO THE Accouf4TS
FOR THE YEAR ENDED31 DECEM8ER2021
7 EKpendllu￿ on r41$1fv8funds
Group8nd (horhy
2028
2022
Stsging fundraising event5
St3ff costs
Support costs
Governancec05t5
74.0
227.6
65.9
14.5
251.0
39.6
13A
Eyndlture on ralsln8 funds
a48.0
An￿y$1$bYfvtt￿
Restricted fund5
Unrethrted funds
348.0
348.0
38Z.O
382.0
8 Expendftureon ¢haritable •rtNiti
Prov151Dn of Info
&support
Dliltal
Innov•t￿n$
Ra151r4
•waweness
CornrNnlty 5vpportln8 our
support youog people
Z013
1023
£'o
Total
ZOZJ
20ZJ
1023
2023
Dlrert costs
Staff ¢osts
19.1
61.2
28
138.7
268.0
191.9
748n
share ofsupportwsts (see note91
118.9
39.6
39.6
2773
Shareof 8overnance c05ts (see note91
13.4
13.4
46.9
415.4
80.3
299.5
141.
1,181
Analysb tsyfvnd
Restricted funds
Unrestricted funds
33.4
382.0
415.4
OA)
299.5
2995
10.4
131.4
141.8
49.6
1,132.3
1.181.9
74.5
60.3
244.9
244.9
Prylslon of lrfo
& support
itsi
R•l$lng
•w•renESS
Communlty Supportlngour
support yOYni PEople
Total
Group
1021
£'ooo
2012
2022
2021
Direct Costs
Staff costs
48.6
246.7
23.7
51.1
58.5
299.8
10.0
7S.2
14th8
759.3
92.5
Share of 5UPPQrt costs (see note91
131.8
197.
65.9
65.9
46L4
Share of8ovemano costs note 91
14.5
5th6
441.6
74.8
564.6
172.8
158.3
1,412.1
alysis byfund
Resirictedfunds
Unrestdrted funds
24.7
416.9
441.6
74.8
10&6
1,303.5
1.411.1
564.6
564.6
172.8
In.8
149.2
158.3
74.8
27

NAnONALAHEUMATOID ARTHRIT1S50CIETY
NOTESTO THEACCOUNTS
FOB THE YEAR ENDED31 OECEMBER2023
8 Exptndiiur*c•¢h•ritJblE aCtl¥ltles
Cfvarlty
p￿￿5￿1n of Info
&support
DIO1
R¥L%ln8
I￿rEnEsS
cornmunlty 5upportlngour
SUPPDrt young people
1023
ZOZ3
inhDvatiOnS
Total
2023
2028
2023
2013
Dlrect costs
Staff costs
Share of 5UPWJrtC05ts IseÈ note91
Shareof8ovemanre Costslsee nots91
54.8
268.0
19.1
61.2
28.5
138.7
11&9
109.7
748.0
277.2
191.9
39.6
B8.2
39.6
13.4
13.4
13.4
415.3
199.5
Z4Qg
141.B
181.8
Anatysls byfvnd
Re5trlctedfunds
Unrestrlrtedfund5
33.4
381.9
415.3
10.4
131.4
141.8
419.6
1,132.2
1,181A
74.5
299.5
299.5
244.9
8D.3
PrLwlslfJm ¢)f inlo
& sw>port
Chil141
R•isinE
Community 5upportlnB our
&UPPDrt peDple
Total
20ZZ
2022
2022
2022
2022
Oirettcosts
5tsff costs
5hareof svpwrtcostslsee note 91
SharEof govemance rostslsee note 91
23.7
51.1
5&5
10.0
75.2
140.8
759.3
461A
246.7
131.8
92.S
197.8
11.9
14.5
14.4
48A)
4J*Q
74.
A7L8
ATraly51sbyfund
estricted fund5
Unre5trtctedfwds
74.8
OA)
1¢)&6
I,3￿.9
1.409.5
414.3
439.0
S64.6
172.8
172.8
1419.2
158.3
74.8
28

NATIONALRHEVMATOID ARYHRITIS50CIETY
NOTESTOTHEACCOU14TS
FOR THE YEAR ENDED81 OECEMBER2023
9 Supportcosts
Group
SupportCOSt5 Governancecosts
2013
Toi•l
1023
SypportW5t5 G¢J¥ewnvKe<051¥
2022
2022
Totsl
zozz
Staff costs
36.$
36.5
88.2
86.8
24.3
26.3
41.8
51.7
34.0
34.0
88.1
86.8
22.1
263
41
Sl.7
97.6
145.5
IOQ.6
56.5
Office
Professional andcon5ultancyfees
Irre¢oveftbleVAT
otheroverhe3ds
Depredatlon &dllapldatlons
IDsurance
Audiiois. rerwneration..
- Atsdiifees
- Other services
145.5
114.2
565
73.1
son
50.0
17.0
17.0
15.8
15.8
31&9
3771
$17.3
65A
592A
Analysed between
Fundra15In8 InDie 71
Chadtable artlvitieslmte 81
3g.6
13.4
53.0
65.9
14.5
277.3
46.9
324.2
461.4
5110
31&9
6thJ
37Y.2
5Z7.3
592.4
The above c05tswere allocatedona headcountb35ty.
Chority
S*port Costs Go¥em•rtt¢ost5
2023
2023
Support costs Go¥ernaThEe￿5ts
2021
zou
£'o
Total
Z022
É'ooo
34.0
97.6
1415.5
114.1
56.5
73.1
50.0
2023
Staff cv5ts
36.5
88.2
86.7
88.2
8&7
22.1
2&3
41.8
51.7
97.6
145.5
ofriLE
profesS￿nal consumaw fees
Irre¢overatrJe VAT
other oveiheads
DekYeclBiion & dilapidatlons
104.6
56.5
41.8
51.7
50.0
Abditors. remunerèih)n'.
Audlt fees
- other￿rVIceS
Trustee*ipenses
17.0
13.2
13.1
316.8
377.1
SZ7.3
atysed tetYJe
FLmdralsln8 Inote 71
tharltable actIv￿leS (note81
39.6
13A
53.0
145
277.2
46.9
324.1
461.4
480
509.4
316.8
377.1
527.3
615
$89.8
The 3bovec05tswere albcared on a headcount ba515.
10 Tiustees
NoDeofthETwsteeslnoranypersons connettedwith theml receNEd anyrernuneration duringtheyear. ard Itrustee wasrelrnbjrsed a t¢tal of £12
travell1￿ expense$12022'. £nS11.

NATIONAL RHEUMATOID ARTHRm5 50aFtY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDEO 31 DECEMBER 2025
11 Employee5
Number of employees
2022
Number
Number
The werage monthly numberof employees durfngthe year was:
All ernployees- Group and Charity
30
31
The avera8e monthly number of full-time equivalent employees during the yearwa5'.
All employees- Group and Charity
26
27
Empli)yment ¢osts
Group
2023
thar]ty
2022
2022
Wages an¢J salarles
Social security
Pension costs
910.6
46.8
78.1
1.035.5
905.6
83.4
31.8
1,020.S
910.6
46.8
78.1
1.035S
905.6
83.4
31.8
1.020.8
The total amount of redundancy payments made bythe Company in the yearwas £5,10012022.. E5.4991.
The numberof employees who received total employee beneffts (excludin8 employer pension tostsl of more than £60,000 is
as follows..
2013
Numbtr
2022
Number
E60,001- £70.000
£70,001- £80.000
Remuneratlon of key rnan¥8emeni personnel
The remuneration of key rnana8ement personnel is a5 follows..
2023
2022
Aggregate Compensatio
184.9
171.4
30

NATIONAL RHEVMATOIDARTMR￿I55OCI
NOTESTOTHE ACCOUNTS
FOR TH£YEAR ENDED 31 DECEMBER 2023
12 Netgainslllossesl on investment5
2023
2022
'TrJo
65.8
RevaluaUon of investments
1141.51
13 Tanglble and IntanBible flxed a55ets- Group and Charlty
Intsn8lble assets
Tangible a55et5
W¢bslte development
Improvementsto
property
Fixtures, ffitting5 &
equlpmeht
Total
tanwble
assets
£'ooo
£'ooo
£'Mo
Cost
At 31 December 2022
Additions
Disposa15
134.8
25.8
54.7
80.5
At 31 December20Z3
134.8
25.8
58.7
DepTeciatlon
AL 31 D￿e11}bel 20ZZ
Charge for the year
Disp05als
75.2
Z9.5
33.6
13.0
18.1
At 31 DKember ZO25
108
41.2
47.6
carr￿￿8 amount
Al 31 December 2023
26.0
19A
17.5
At 31 December 2022
59.6
26.5
si.o
14 Flxed asset Investments- Groyp •md Charlty
2023
£'ooo
2022
Listed investments
Marketvalue at ljanuary
Additions lincluding Interest rdnvettedl
Revaluation
MarketvaluÈ at 31 December
912.5
30.2
1,025.6
28.5
1141.61
912.5
65.8
1,008.5
15 Financial instruments
2023
£,￿0
2022
£'oL
Carrwng amountof financial assets
In5Erumenrs rneasured at arn9rn5ed c05t
Instruments measvred atfairvaluethrough profit or kns
1.008.5
912.5
Carrylng amount of finantsal liobilitie5
Measured at amort15ed cost
97.5
102.0
31

NATIONAL RHEUMATOIDARYHRrris SOCIETY
NOTESTO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2023
16 Debtors
Group
Charity
2023
£'ooo
2022
2023
Z022
'ooo
AmountsfallinB due wlthln orbe year..
Trade debtors
Arnounts Dwe(J bvgroup undertèkin85
Otherdethors
p￿payrnents and accrued In¢ome
17.7
17.7
337.5
48.6
317.4
35.4
337.5
48.6
317.4
35.4
397.7
402.9
Otherdebtors Include £25.3k relating to lon8 temi debtors rece*vable In greaterthan one year'stlme
17 Creditors: amounisfallFnE due wlthln orte year
fjroup
Charity
2023
2022
£,0￿)
2023
£'ooo
2022
Trade credltors
Other taxesznd social *curity Costs
Other£redltors
Accruals and defwred income
15.7
27.7
55.7
26.1
17.2
14.2
53.3
31.5
15.7
27.7
55.7
25.6
17.2
14.2
51.3
31.5
125.2
11&2
124.7
114.2
2023
2022
£'ooo
Deferred income included in the flnanclal statements asfollows:
At l January
Movement during the year
At 31 December
13.8
13.8
18 Retirement benefit sthemes
Defined ¢)ntribution xhemes
Thecharrty operates a defined Contribu￿9￿ pension schernefor all qualltyng employees. The 6$sets of the scherne are held
5eparatelyfrom those of the Charity in an independently administered fund.
The charge to profit or loss In respett of defined contrfbution scheme5 was £46.8k12022.' £31.8kl.
32

NATIONAI RHEUMATOIDARTHRIMSSOOETY
NOTESTOTHEACCOUNIS
FOR THE YEAR ENDED31 DECEMBER ZOZI
19 Fund veiorKli•tlon
The Inc￿ef￿N￿ofthechantyITrEIUde re5viued f￿r￿sCoMpr￿1ngthcfOll0Wi￿ unexpended b31ancesof donatK)ns andBrants held ontru5t for5peclnc
purpose5.'
Unrestrlcied Fund5
Mo*m*ntlnfunds
In¢Dmlng Resource5
r4sollrcÈ$
ewpended Tra*￿t01
2013
2028 funds 2021
£'ooo
alaKeati
Jonu*ry ZOZ3
Bapance at 31
DeRrnber2023
£'o
Unrestrlcred
DesIgna￿d-JuveThh1e Idiopathic Athdtisactiwties
Deslgndted-to coverpredirtedopeiatinglossesin nextyear
De55Enated-to coverpoteDtSal ￿n￿SIM￿ntIo5ses
1.369.1
1,809.3
10.0
1418.81
42.3
375.0
ao
1.397.4
I￿.0
I￿.0
SCO.0
Iw,o
IS9￿1
1*19.3
IIA14.51
1.99?.4
Mov•ntntlnfunds
Ineomini R•5Durcei
Transfèrol
resou￿e5
eKpended
funds
Z022
Z02Z
Tho
Balanceati
January 1022
Balancfyat31
December2022
2022
£'DJo
£'ooo
un￿$trI￿ed
Desi￿8ted-jv¥enltse Idh?pathl¢Arthriti5 activitie5
Deslgnated-to coverprediiled OPOratlTr8 lossesin nextyear
Oesl8n3ted-io coverpoienti31 Investrnent10sses
1.871.2
on
L553.4
38.2
11,784.21
142.91
1271.31
1.369.1
125.0
io).0
125.0
ioo.D
L8?1.2
Ik6Z7.11
Re$¢ri¢itd Fynds
Mo¥ementlnfunds
IDcvrninB Resource5
Transferof
S¢luT(es
eNpended
funds
2023
Balance at I
January2023
Oalance &t31
DKember1023
1023
£OL
InfOrma￿on¥k1e0l￿ H5ndl
Enhanced Rightstart
Str￿ tnana8ement pr0￿ct
Blood MonrtorinKpublicativn
11.3
115
M15sion prolett
QLab project
20
15.0
19.4
48.7
149.61
Mo¥emeTht luf
BalaTh￿at i
JiThJary ZOZI
IKom1￿ Resources
i*sour¢es
qwended
2022
21)22
£'oc
TThn51erof
fund5
zz
Bakn¢eat31
DKember2022
DeVelo￿eniof e￿arnIng$V1te
ljevelopmem of onllne self.manaeemEntCOLrse Inscouand
Information wdeo In Hindi
elood Monitorlng publkatlon
O¥v¥luyiiientofexErtlSE 5UPPVrt app
Enhanced Ri8ht5tart
JIAlma8ined Futures project
Reprintof PIedKI￿SèOOk￿t
JIA ￿de0
stres5 mana6emeni prole
15.0
149.01
on
15.0)
14.1
10.0
10.0
22.6
10.5
3Q9
19.4
33

NATIONAL RHEUMATOID ARThRITIS SOCIETY
NOTE5 TO THE ACCOUNIS
FOR THE YEAR ENDED 310ECEMBER 2023
20 Analysis of a5set5 between fvnds- Group
Restrlcted
E'QQQ
Unrestrlrted
Total
£'ooo
Fund balances at 31 December 2023 are represented by..
Tangible fixed assets
Investments
Current assetsllliabllltlesl
36.9
1,008.5
952.0
36.9
1,008.5
972.0
20.0
20.0
1,997.4
2.017.4
Fund balanw at 310ecembtr 2022 are represented by..
Restrirted
£'ooo
Vnrestritted
f'ooo
Total
f'ooo
Tanglble fTxed assets
Investments
Current assetsllllabilitlesl
51.0
912.5
630.6
51.0
912.5
650.0
19.4
19A
1,594.1
1,613.5
Analysls of Det assets between funds- Charity
Restrirted
£'ooo
Unrestri¢ted
£'ooo
Total
Fund balan¢e5 Ot JI De¢ember2023 are represented bv:
Tangible fixed a55ets
Investments
Current asset5111iabilitiesl
36.9
1,008.5
954.7
36.9
1.008.5
974.7
20.0
20.0
2,000.1
Z.020.1
Fund balances at 31 December2022 are represented bv:
Restricted
Unrestricted
Totsl
£'ooo
51.0
912.5
633.2
Tan8Sble fixed assets
Investments
Current assets/lliabilitiesl
51.0
912.5
652.6
19.4
19A
1,596.7
1.616.1
21 Cornmitm•nts under operatln8 leases
At the reportin8 end date the group and charfty had out5tandlng commltments forfuture mlnlmum lease pa￿ntS
under non-cancellable operatlng leases. which fall due as follows:
2023
2022
£'ooo
Within one year
Between two and five years
C￿erfiVe years
47.6
77.1
31.6
112.5
IZ4.7

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 20Z3
22 SubsidSary company
The charity owns the whole of the issued ordinary share capltal of NRAS Communlty sen1￿e$ Ltd (company
number.. 89532471, a cornpany reglstered in England. The subsidlary is used for non-prlmary pursy)se tradlng acrivIt￿s.
All activities have been £onsolidated on a line by line basis in the Statement of finènc181 actfvities.
The total net profit Is glfted to the charity.
A Summary of the results of the subsidiary is shown below=
2023
2022
Turnover
Cost of saJES
Gross profit
Administrative expenses
Net profk
10.ii
10.ii
12.61
Retoined earning5 brought forward Sn 5ubsldlary
Gift aid to National Rheumatold Arthritls Society
Retsined earnings carrled forward In subsldlary
12.61
14.81
12.6
12.71
The assets and Ilabilities were..
The aggregate olthe assets, Ilabilities and funds was..
Assets
abillties
Tot¥1 n•t as5•ts
17.21
12.61
12.?)
Called up Sha￿ cèpital
Profitand loss reserve
12.71
12.71
12.61
23 Related party transactlons
There were no related party transactions In the year12022.' nill ￿QuIrIng disck)wre.
24 Capltal CommltmÈnts
As at 31 December 2023 the Charity had capital cornmitments of £nil12022.. £nill.
35

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED31 DECEMBER 2023
25 Cash generated from/ (used In) opèrations
Group
Charity
2023
£'ooo
2022
£'ooo
2023
2022
£'ooo
Surplusl Ilossl for the year
Adjustments for..
Investment income recognised in profit or loss
Fair value gains and losses on investments
Gift aid donation from subsidiary
Depreciation and impairrnent of intangible fixed asset.,
Depreciation and impairment of tangible fixed assets
Movements in working capital..
Ilncreasell decrease in debtors
Incieasel Idecreasel in creditors
403.9
1288.61
404.0
1281.21
134.71
165.81
128.61
141.6
134.71
165.81
128.61
141.6
14.81
33.7
15.3
33.6
18.1
33.7
15.3
33.6
18.1
16.11
46.3
16.11
10.5
47.3
Cash eenerated froml{used inl operatSons
358.0
178.51
359.6
173.91
26 Analysis of changes in net funds
At start of
Cash flows
At end of
yQ2r
Cash and tash equtvalents
308.9
358.5
667.4
Total
308.9
358.5
667.4
36